CHAPTER 1. INTRODUCTION
1.1. Market Definition
1.2. Executive Summary
1.3. The Scope of the Study
CHAPTER 2. RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3. MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5. Degree of Competition
3.3. PESTLE Analysis
3.3.1. Political
3.3.2. Economical
3.3.3. Social
3.3.4. Technological
3.3.5. Legal
3.3.6. Environmental
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weakness
3.4.3. Opportunities
3.4.4. Threats
3.5. Y-O-Y Analysis
CHAPTER 4. MARKET DYNAMICS
4.1. Market Drivers
4.1.1. New developments in animal models
4.1.2. The rise in pharmaceutical and R&D activities
4.1.3. Strict government regulations for animal testing
4.2. Market Restraints & Challenges
4.2.1. Disadvantages associated with animal toxicology testing
4.2.2. Regulations for the use of animal toxicology in research
4.3. Market Opportunities
4.3.1. Increase in demand for humanised animal models
4.3.2. Rising research in oncology and personalised medicine
CHAPTER 5. GLOBAL INVIVO TOXICOLOGY MARKET – BY TESTING TYPE
5.1. Introduction
5.2. Acute Toxicity Testing
5.3. Sub-Acute Toxicity Testing
5.4. Sub-Chronic Toxicity Testing
5.5. Chronic Toxicity Testing
CHAPTER 6. GLOBAL INVIVO TOXICOLOGY MARKET – BY TESTING FACILITY
6.1. Introduction
6.2. In-House Testing Facilities
6.3. Outsourced Testing Facilities
CHAPTER 7. GLOBAL INVIVO TOXICOLOGY MARKET – BY PRODUCT
7.1. Introduction
7.2. Instruments
7.3. Consumables
7.3.1. Reagents & Kits
7.3.2. Animal Models
7.3.2.1. Mice Models
7.3.2.2. Rat Models
7.3.2.3. Other Animal Models
CHAPTER 8. GLOBAL INVIVO TOXICOLOGY MARKET – BY TOXICITY
ENDPOINT
8.1. Introduction
8.2. Immunotoxicity
8.3. Systemic Toxicity
8.4. Carcinogenicity
8.5. Genotoxicity
8.6. Developmental and Reproductive Toxicity (DART)
8.7. Other Toxicity Endpoints
CHAPTER 9. GLOBAL INVIVO TOXICOLOGY MARKET - BY GEOGRAPHY
9.1. Introduction
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.2.3. Mexico
9.2.4. Costa Rica
9.3. South America
9.3.1. Brazil
9.3.2. Argentina
9.3.3. Chile
9.3.4. Columbia
9.3.5. Others
9.4. Europe
9.4.1. U.K.
9.4.2. Germany
9.4.3. France
9.4.4. Italy
9.4.5. Spain
9.4.6. Russia
9.4.7. Netherlands
9.4.8. Switzerland
9.4.9. Poland
9.4.10. Others
9.5. APAC
9.5.1. China
9.5.2. Japan
9.5.3. India
9.5.4. South Korea
9.5.5. Australia & New Zealand
9.5.6. Malaysia
9.5.7. Singapore
9.5.8. Others
9.6. Middle East & Africa
9.6.1. UAE
9.6.2. Saudi Arabia
9.6.3. Iran
9.6.4. Iraq
9.6.5. Qatar
9.6.6. South Africa
9.6.7. Algeria
9.6.8. Morocco
9.6.9. Nigeria
9.6.10. Egypt
9.6.11. Others
CHAPTER 10. GLOBAL INVIVO TOXICOLOGY MARKET - COMPANY PROFILES
10.1. Wuxi Apptec
10.2. The Jackson Laboratory
10.3. Eurofins Scientific
10.4. Envigo Corporation
10.5. Danaher
10.6. Data Sciences International
10.7. Lab Corporation
10.8. Charles River Laboratories
10.9. PerkinElmer, Inc.,
10.10. SRI International
10.11. Taconic Biosciences
10.12. Thermo Fisher Scientific
10.13. Bio-Rad Laboratories
10.14. Cyprotex PLC
CHAPTER 11. GLOBAL INVIVO TOXICOLOGY MARKET - COMPETITIVE
LANDSCAPE
11.1. Market Share Analysis
11.2. Strategies adopted by top companies
11.3. Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 12. MARKET INSIGHTS
12.1. Industry Experts Insights
12.2. Analysts Opinions
12.3. Investment Opportunities
CHAPTER 13. APPENDIX
13.1. List of Tables
13.2. List of Figures
